Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells.
To determine the regulatory effects of estrogen and cytokine IL-6 and IL-8 on the growth of epithelial ovarian cancer (OVCA), we first examined the status of estrogen receptors (ERalpha and ERbeta ), IL-6 receptor (IL-6Ralpha and gp130), and IL-8 receptor (IL-8RA and IL-8RB) on five epithelial OVCA cell lines by semiquantitative RT-PCR and Western blot analysis. Results showed that the expressions of these receptors were variable on the five cells. Those OVCA cells expressing the receptors were selected to study related molecular mechanism. MTT assay was performed to observe the effects of 17beta-estradiol (E2), IL-6 and IL-8 on cell proliferation. We discovered that E2 markedly promoted the proliferation of CAOV-3 and OVCAR-3 cell in a time- and dose-dependent manner. Tamoxifen (Txf), an ER inhibitor, completely blocked the proliferation of the E2-induced cells, and IL-6- or/and IL-8-neutralizing antibody only showed partially blocking activity. IL-6 and IL-8 were able to significantly stimulate CAOV-3 and OVCAR-3 cell proliferation in a time- and dose-dependent manner, which had a potential synergistic effect on CAOV-3 cells but not on OVCAR-3 cells. The cell proliferation induced by these two cytokines was abolished completely by their specific neutralizing antibodies, partially by Txf, but not by unrelated goat IgG. Taken together, our results suggested that estrogen, IL-6 and IL-8 could modulate OVCA growth by forming a reciprocal cascade with amplifying effect.
Wang
Yue
Y
Department of Immunology, Tianjin Medical University, 300070, China.
Yang
Jie
J
Gao
Yan
Y
Du
Yongrui
Y
Bao
Leyuan
L
Niu
Wenyan
W
Yao
Zhi
Z
D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D050822:Cytokine Receptor gp130 / Q000096:biosynthesis / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004847:Epithelial Cells / Q000276:immunology / Q000473:pathology; D004958:Estradiol / Q000276:immunology / Q000494:pharmacology*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects / Q000276:immunology; D006801:Humans; D015850:Interleukin-6 / Q000276:immunology / Q000494:pharmacology*; D016209:Interleukin-8 / Q000276:immunology / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000473:pathology; D011960:Receptors, Estrogen / Q000096:biosynthesis / Q000276:immunology; D023062:Receptors, Interleukin-8A / Q000096:biosynthesis / Q000276:immunology; D023063:Receptors, Interleukin-8B / Q000096:biosynthesis / Q000276:immunology
C494199:IL6ST protein, human; D015850:Interleukin-6; D016209:Interleukin-8; D011960:Receptors, Estrogen; D023062:Receptors, Interleukin-8A; D023063:Receptors, Interleukin-8B; D050822:Cytokine Receptor gp130; D004958:Estradiol